I am grateful for my hon. and learned Friend’s intervention. The irony is that, when the Bill first started in the House of Lords, the figure of £7,000 was debated, but the assumption was subsequently revised down to £2,000 and then back up to £7,000. Under the original £7,000 assumption, however, the DWP calculations were exactly the same as they were when £2,000 was being discussed. Unfortunately, it is completely unclear to anyone who has paid any attention to this Bill precisely who is paying for this, what it includes and how the victim can still be put at the heart of it all.
On one particular point, I pay tribute to the insurance industry. It improved over the years in its financing of research into mesothelioma. This began when I was working at Aviva—I am not talking all the credit for it, but it did—as an attempt to stop the last Government from following the lead of Scotland and legislating too harshly on other asbestos diseases such as pleural plaques. As it happens, I supported the last Government’s resistance to following Scotland and was pleased that the top four insurers contributed to research funding into mesothelioma instead. That said, the funding runs out next year, and there has currently been no voluntary commitment—not just from the top four, but from all EL insurers—to contribute further money into research. I think that is a dreadful shame, which will have a major impact on future treatments to alleviate suffering at a time when we expect meso-diagnosis to spike. I share the views of the British Lung Foundation—supported, I believe, by the Association of British Insurers—about building the continuation of funding directly into the Bill. It is sad that a £4 billion EL industry cannot make a voluntary offering, spread equally across all insurers. If that is so, we parliamentarians now have a statutory opportunity to force them to do so.